Korian Delivered Solid Results in 2022, With a 6.2% Organic Growth and a 13.4% EBITDA Margin, Driven by Its Transformation Plan Launched in 2019 and Priority Given to Quality and Social Performance

21 Feb 2023 18:21 CET

Issuer

CLARIANE SE

Regulatory News:

Korian (Paris:KORI):

  • Quality and social performance: Ahead of schedule for 2023 ESG targets
    • Quality:
      • 68% of network certified ISO 9001 (2022 initial target: 50%); 100% of healthcare facilities in France classified A or B by the Health Authority
      • Average staff ratio in nursing homes of 0.78 per resident in France
      • Net Promoter Score (NPS) reaching 36, up by 2 points
    • Human Resources:
      • Professional training: 6,800 employees (i.e. 11.8% of total employees) in a graduating training programmes (2023 initial target: 10%; x3 vs 2019)
      • Health & safety at work: work accident frequency rate down 15%
      • Improvement of employees’ engagement rate at 78 (+1pt vs 2021)
      • “Top Employer” certification in the Group's four main countries
    • Diversity:
      • 56% women in top management positions of the Group (+ 10 pts vs. 2019)
    • Environment:
      • -24% of reduction in CO2 emissions (vs. 2019) and -9% of energy consumption (vs. 2021)
  • Revenue growth in all three segments, with overall organic growth of 6.2% (reported growth of 5.6%), supported by the transformation plan initiated in 2019
    • Long-term care: increase of occupancy rate by 2.3 points and 3% increase in the number of people cared for; almost 40% of the network has been restructured and modernised since 2016
    • Healthcare: delivery of 13 additional projects to support specialisation and the development of outpatient activity; acquisition of the Spanish platform Grupo 5 to strengthen the mental health activity; 20% increase in the number of patients
    • Community care: Ages&Vie network in France now with 1,875 beds in operation; high growth in the homecare network (people cared for x2); the Petits-fils network in France opened 40 new branches, bringing the total to 253
  • Resilient operating performance reflected in improving EBITDAR in amount and a solid cash generation:
    • EBITDAR of € 1,091 million (margin rate at 24.1%) and EBITDA of €607 million (margin rate 13.4%) in an environment marked by accelerating inflation
    • Strong cash generation with € 371 million of Free Cash Flow, due to improving working capital requirement
    • Net result of pursued activities of €66.9 million including non-recurring costs related to the transformation plan
    • Real estate value of €3.5bn, after independent Cushman&Wakefield assessment
    • High level of liquidity at €1,234 million, including fully undrawn RCF
    • Solid balance sheet: operational leverage of 3.7x and LTV 55%, without a new real estate partnership during the year
    • Proposed dividend: distribution of € 0.25 per share reflecting a 50% payout ratio (pre-IFRS16)
  • Outlook
    • Benefiting from the effects of the transformation plan, expected organic growth of revenue more than 8% in 2023 and more than 5% in 2024-2025, with EBITDAR stable in 2023, growing in 2024 and 2025 in line with revenue
    • Alignment of investment policy with self-financing capacity from 2024 onwards. The Group’s financial leverage is expected to be below 3.5x in 2023, and at around 3x in 2024 and 2025.
    • In the context of the move to a purpose driven company, A new corporate project (2023-2025) and ESG roadmap will be presented on 31st of March 2023

Sophie Boissard, CEO of Korian, stated : “After two years marked by the Covid pandemic, 2022 was also a year of unprecedented challenges for our sector. I would like to recognize the outstanding commitment of the whole Korian community and of our stakeholders, which has enabled us to remain focused on what is essential despite the turbulence: the quality of care provided and our social performance. Thanks to the investments made in our networks and the complementary nature of our expertise in geriatrics, post-acute and rehabilitation care, mental health and home care, we are achieving a solid fiscal year 2022, marked by unprecedented organic growth and an operating model which demonstrated its resilience in a high inflation environment.”

FINANCIALS

     

€m

FY 2022

 

FY 2021

 

Growth

 

Organic
growth

 

 

 

 

 

 

 

Revenue

4,534.1

 

4,294.8

 

5.6%

 

6.2%

 

 

 

 

 

 

 

France, Spain, UK 1

2,226.1

 

2,168.3

 

2.7%

 

4.4%

Germany

1,082.0

 

1,067.5

 

1.4%

 

5.6%

Benelux 2

667.0

 

587.0

 

13.6%

 

14.0%

Italy

 

559.0

 

472.1

 

18.4%

 

6.4%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBITDAR - excl. IFRS16

 

1090.7 (24.1%)

 

1071.1 (24.9%)

 

1.8%

 

 

EBITDA - excl. IFRS16

 

607.1 (13.4%)

 

597.2 (13.9%)

 

1.7%

 

 

EBITDA - incl. IFRS16

 

1003.2 (22.1%)

 

999.3 (23.3%)

 

0.4%

 

 

Operating Free Cash Flow

 

371

 

239

 

55.4%

 

 

ACTIVITY

   

2021

 

2022

 

Variation

 

 

 

 

 

Nursing Homes Occupancy (December)

85.5%

 

87.8%

 

+2.3pts

Net Promoter Score

34

 

36

 

+2pts

 

 

 

 

 

ESG

   

2021

 

2022

 

Variation

 

 

 

 

 

% facilities certified ISO 9001

29%

 

68%

 

+39pts

% facilities with "Positive Care"

80%

 

97%

 

+17pts

% employees in graduating programme

9.7%

 

11.8%

 

+2.1pts

Average tenure (years)

7.4

 

7.3

 

-0.1

Key operational highlights

Over 2022 Korian has continued to develop its network to best respond to the expanding needs for care across Europe:

  • Long term care:
    • Acceleration in adapting the network to high dependency needs with 65 facilities refurbished over the year, and 56 facilities have been sold or closed over the last 24 months (around 8% of the network).
  • Healthcare:
    • Pursuit of the modernisation of Korian network with notably 13 clinics built or extended in France, bringing the number of facilities restructured to c.50% of the network at the end of 2022. All French clinics now operating under the Inicea brand.
    • Acquisition of highly specialized clinics (including Mental Health) in Italy, with strong outpatient capacity: Italian Hospital Group (IHG) in Lazio and Borghi in Lombardia.
    • Development of the European mental health platform with the integration in Spain of ITA Salud and the acquisition of Grupo 5 (closed in January 2023), a high quality and complementary network with embedded growth.
  • Community Care:
    • Ages&Vie co-living in France reaching 243 houses with 79 built in 2022, from 44 in 2018.
    • Signature of a second Ages&Vie equity partnership with Banque des Territories and Credit Agricole
    • Strong growth of home care activities with 330 agencies (+60 in 2022), including 253 in France where the Petits-fils franchise has become the largest private network, with more than 15,000 clients at the end of 2022.

At end December 2022, Group’s network is composed of 87,994 beds, after the disposals and closings of 69 facilities in the last 24 months. During this period of 2 years the Group has also delivered around 3,500 beds through greenfield development.

Key ESG highlights

Korian set out an ambitious ESG roadmap in 2019 with the majority of the targets set for 2023. At the end of 2022 a large number of these targets are already achieved.

In terms of quality of care 68% of the network is certified IS0 9001, in the context of a program started in 2019, and 97% of the network has achieved the internal label “Positive Care” from 72% in 2019.

Human resources policies are bearing fruit as 11.8% of employees are now in graduating training programmes from 4% in 2019 and in health and safety there is a marked drop of 15% in the frequency of work-related accident. The number of women in the top 150 executives of the company has now reached 56%.

2022 has also been marked by an active social dialogue and a new milestone in employee’s engagement with the Group’s first employee shareholding scheme:

  • Korus: a successful pan European shareholding plan with 15% of employees subscribing (25% in France) and now representing 2.8% of shareholding
  • Following the transformation into a European company, the signature of an agreement to establish a European Company Works Council

Finally, the Group supports local communities and plays an active role in protecting the environment and in 2022:

  • 80% of purchasing was done locally in the countries of the Group and 99% of our facilities are involved in local projects
  • the Group’s CO2 emissions have been reduced by 24% compared to 2019

****

The consolidated audited financial statements for 2022 were approved by the Board of Directors at its meeting of 21st February 2023. The Statutory Auditors have issued a report with an unqualified opinion.

The consolidated financial statements were prepared in accordance with the IFRS 16 standard. For purposes of comparability, the financial information below is presented excluding the application of IFRS 16.

2021 figures restated to reflect impacts from the final IFRIC decision relative to customization and configuration costs of SAAS solutions, and the impact of IFRS5 discontinued operations

****

Q4 Revenue

Revenue in Q4 2022 increased by 6.6%, at 1,190.0 million euros of revenue. The organic growth was robust at 8.0%. This was driven notably by activity recovery in the Long-Term Care activities, with 2.3 points rise in occupancy rate at group level from 85.5% to 87.8% in December 2022. It is also reflecting the capacity of the Group to pass-through higher costs in prices, with notably the first impact from salaries costs pass-through in Germany.

Full year revenue and results 2022

In 2022, revenue totalled €4,534 million, up 5.6%, with a -3.6% impact from disposals and closings in the last 24 months, part of Korian efforts to streamline its asset portfolio in the Long-Term activities. Adjusted for the decrease of revenue compensations and the impact of disposals and closings, the revenue growth is 11.0%, reflecting a strong underlying activity growth.

Organic growth of 6.2% and 8.1% adjusted for revenue compensations variations, reflects positive dynamics of all activities:

  • Long-Term care: a 9.3% compensation-adjusted organic growth, driven by continued occupancy recovery throughout the Group, and continued ramp-up effects in Netherlands, Spain and the United-Kingdom
  • Healthcare: compensation-adjusted organic growth is 5.1%, in an activity environment which has normalised, driven by continued enhancement of the network, with notably ambulatory activities growing by 18% at c. €152m revenue, i.e. c.14% of Healthcare revenue.
  • Community Care: Organic growth is 7.5%, with a high growth trajectory fuelled by strong demand pressure in home care as well as assisted living facilities development

The Group’s EBITDAR in 2022 is €1,090.7m and the EBITDAR margin is 24.1% reduced by 80 basis points on 2021 reflecting the impact of higher costs passed through in the revenue, notably due to the salary reset in Germany, time lag between tariff increase and costs inflation, and energy costs increase, which represent c.€20m.

By country:

  • In France, Spain and the United-Kingdom 3 , revenue growth is +2.7%, and 4.4% organically. Adjusted organic growth is 6.0%, fuelled by nursing homes occupancy recovery to 88% in December 2022 in France, as well as normalisation of the Healthcare activity, after pandemics related disruptions in H1 2021. The EBITDAR margin is recovering by 110bps from 24.8% to 25.9% mainly as a consequence of higher occupancy offsetting staff costs continued increase.
  • In Germany, revenue increased by +1.4% and 5.6% organically. Adjusted organic growth is 7.5%, mainly reflecting the price increase consecutive to the important salary reset effective from September 2022. Limited reported growth is the effect of the disposals of 30 facilities during the last two years.
  • In the Benelux 4 region the reported growth remained high at 13.6% driven by the organic expansion in the Netherlands, as well as dynamic occupancy progress in Belgium. Organic growth is 14.0%, and 17.6% on an adjusted basis. The EBITDAR margin decreased to 21.3% (versus 23.6% in 2021) following important pass-through effects, notably in relation salaries increase.
  • In Italy, revenue was up by +18.4% driven by acquisitions with a continued focus on healthcare services and a local cluster approach in key regions. Organic growth was very resilient as well at 6.4% due to high nursing homes occupancy rate and dynamic healthcare activities, notably in outpatient care which register a 17% growth. The EBITDAR margin showed resiliency at 21.0% (versus 20.5% in 2021) in spite of a year marked by costs inflation.

Korian’s EBITDA totalled €607.1 million in 2022, up 1.7% on 2021 (-50bps in margin from 13.9% to 13.4%), a resilient performance on the back of a stability of rental costs, reflecting Korian active rent management and past investments in Real Estate. Including IFRS16 impact, EBITDA is €1,003.2m reflecting a 22.1% margin, down 120bps vs 2021 in line with EBITDAR margin evolution.

Korian Real Estate portfolio has grown by c.€300m to €3.5bn. The capitalisation rate retained by independent expert has increased from 5.3% to 5.4%, reflecting the resilience of the Healthcare asset class in countries where Korian is present. Owned properties represent c.28% of Korian’s network.

The Group has undertaken an extensive review of its assets to identify any provision risks. This review has not resulted in any significant assets revaluation in its audited financial statements.

Current Earnings before interest and taxes (EBIT) amounted to €315.3 million, i.e. 7.0% of revenue (versus 8.0% in 2021).

Net profit from continued activities totalled €66.9 million (versus €123.4 million in 2021) notably impacted by important non-current expenses in 2022 in relation to the Group’s transformation in France, Germany and Belgium (disposals and closings of facilities).

Solid financial structure

The Group has generated € 371m of operating free cash flow in 2022 reflecting a catch-up effect after 2021 and 2020 levels impacted by the covid crisis. Maintenance or operating capex, included in the free cash flow, represent 2.2% of revenue in 2022.

Korian has maintained a high level of liquidity with € 734 million of cash and €500 million of undrawn credit facilities, over the year Korian has successfully raised c.€620m of debt, of which €215m during the second semester.

Investment in 2022 include €181 million of development capex, stable compared to 2021 as the Group continues to transform its network to add specialised, medicalised equipment and outpatient capacity; €190 million of financial investments through M&A, mainly focused on healthcare with acquisitions in Italy and also in the United Kingdom compared to € 220 million in 2021 and €460 million of real estate capex similar to 2021, of which € 224 million linked to greenfield developments.

The balance sheet of Korian remains strong with a LTV of 55% and an operational leverage of 3.7x, leaving ample headroom compared to the Group’s covenants of 4.5x and showing relative stability of the ratios despite an EBITDA under pressure from inflation effects and the absence of monetisation transaction on the Real Estate portfolio during the year.

The Group’s net financial liabilities increased to €3,775 million from €3,228 million at 31 December 2021. The real estate debt represents € 1,914 million compared to a real estate portfolio value of € 3,455 million (55% LTV).

Perspectives

In 2023 organic growth is expected to reach more than 8% driven by recent transformations and openings, occupancy and activity recovery and increased pricing following the revaluation of care tariffs following increased costs.

Following the significant investments into the network over the last few years, including the development of ambulatory capacity and the opening of new facilities (around 3,500 opened over the last 2 years), Korian currently benefits from a strong embedded growth, which will allow the Group to reduce significantly its capital expenditure over the next few years whilst maintaining a high level of organic growth.

At the same time the amount of EBITDAR is expected to be stable in 2023 compared to 2022, reflecting the pass through of inflation and salary upgrades. In 2024 and 2025 it is expected that the revenue growth will also drive EBITDAR growth, as well as EBITDA pre-IFRS16 growth.

The Group’s financial leverage is expected to be below 3.5x in 2023, and at around 3x in 2024 and 2025, on the back of a self-financing model expected from 2024.

Annual Shareholder Meeting:

The Board of Directors will submit to the next Annual Shareholders’ Meeting to be held on June 15th, 2023, the distribution of a dividend of € 0.25 euros per share, reflecting a 50% pay-out on pre-IFRS16 net result, with an option for payment in new shares.

The Board, acting on the recommendation of the Compensation and Appointment Committee, will also propose the following renewals and appointments in the Board’s membership to the shareholders at Annual Meeting:

  • Mr. Guillaume Bouhours
  • Mr. Philippe Dumont
  • Mrs. Sophie Boissard
  • Dr. Markus Müschenich

Presentation FY 2022 results Wednesday 22nd February 2023 from 9:00 am to 11:00 am CET

New Corporate project and ESG roadmap: 31st March 2023

The link to access the live video webcast is available below. The presentation document will be available on Korian website

Access to join the live video webcast

 

https://channel.royalcast.com/korianen/#!/korianen/20230222_1

 

About Korian

Korian, the leading European care services group for elderly and fragile people. www.korian.com

Korian has been listed on Euronext Paris Section A since November 2006 and is included in the following
indices: SBF 120, CAC Health Care, CAC Mid 60, CAC Mid & Small and MSCI Global Small Cap

Euronext ticker: KORI - ISIN: FR0010386334 – Reuters: KORI.PA – Bloomberg: KORI.FP

1 Including €98.1m revenue in Spain in 2022 vs €64.9m in 2021; and €47.1m in United Kingdom in 2022 vs €20.5m in 2021
2 Including €562.9m revenue in Belgium in 2022 vs €506,0m in 2021; and €104,1m in the Netherlands in 2022 vs €81,0m in 2021
3 Including €98.1m revenue in Spain in 2022 vs €64.9m in 2021; and €47.1m in United Kingdom in 2022 vs €20.5m in 2021
4 Including €562.9m revenue in Belgium in 2022 vs €506,0m in 2021; and €104,1m in the Netherlands in 2022 vs €81,0m in 2021

APPENDICES

2022 FULL YEAR AND Q4 REVENUE

 

Revenue (€m)

 

Variation (%)

 

4th quarter

 

Reported

 

Organic

 

2022

 

2021

 

Growth

 

Growth

France, Spain, United-Kingdom*

 

575.3

 

564.0

 

2.0%

 

4.6%

Germany

 

286.9

 

271.3

 

5.8%

 

13.5%

Benelux**

 

178.1

 

148.7

 

19.8%

 

15.2%

Italy

 

149.7

 

132.9

 

12.7%

 

3.3%

Total

 

1,190.0

 

1,116.8

 

6.6%

 

8.0%

* o/w Spain: €25.0m in Q4 2022 vs €23.1m in Q4 2021, United Kingdom: €14.5m in Q4 2022 vs €6.6m in Q4 2021
** o/w Belgium: €148.6m in Q4 2022 vs €125.5m in Q4 2021, Netherlands: €29.5m in Q4 2022 vs €23.2m in Q4 2021

 

Revenue (€m)

 

Variation (%)

 

Full Year

 

Reported

 

Organic

 

2022

 

2021

 

Growth

 

Growth

France, Spain, United-Kingdom*

 

        2,226.1

 

        2,168.3

 

2.7%

 

4.4%

Germany

 

        1,082.0

 

        1,067.5

 

1.4%

 

5.6%

Benelux**

 

           667.0

 

           587.0

 

13.6%

 

14.0%

Italy

 

           559.0

 

           472.1

 

18.4%

 

6.4%

Total

 

4,534.1

 

4,294.8

 

5.6%

 

6.2%

* Including €98.1m revenue in Spain in 2022 vs €64.9m in 2021; and €47.1m in United Kingdom in 2022 vs €20.5m in 2021
** Including €562.9m revenue in Belgium in 2022 vs €506,0m in 2021; and €104,1m in the Netherlands in 2022 vs €81,0m in 2021

GROUP INCOME STATEMENT

€m

 

2022
Incl. IFRS 16

 

IFRS 16
adjustments

 

2022
Excl. IFRS 16

 

2021
Excl. IFRS 16

 

∆

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

4,534.1

 

-

 

4,534.1

 

4,294.8

 

239.3

Growth%

5.6%

 

-

 

5.6%

 

11.3%

 

-560 bps

Staff costs

(2,718.5)

 

-

 

(2,718.5)

 

(2,525.6)

 

(192.9)

% of revenue

60.0%

 

-

 

60.0%

 

58.8%

 

+120 bps

Other costs

(743.3)

 

18.4

 

(724.9)

 

(698.1)

 

(26.8)

% of revenue

16.4%

 

-

 

16.0%

 

16.3%

 

-30 bps

EBITDAR

1,072.3

 

18.4

 

1,090.7

 

1,071.1

 

19.6

% of revenue

23.6%

 

-

 

24.1%

 

24.9%

 

-80 bps

External rents

(69.0)

 

(414.5)

 

(483.5)

 

(473.9)

 

(9.6)

% of revenue

1.5%

 

-

 

10.7%

 

11.0%

 

-30 bps

EBITDA

1,003.2

 

(396.1)

 

607.1

 

597.2

 

9.9

% of revenue

22.1%

 

-

 

13.4%

 

13.9%

 

-50 bps

Amortisation & Depreciations

(614.7)

 

363.1

 

(251.6)

 

(229.1)

 

(22.4)

Provisions

(40.2)

 

-

 

(40.2)

 

(23.5)

 

(16.7)

EBIT

348.3

 

(33.0)

 

315.3

 

344.5

 

(29.1)

% of revenue

7.7%

 

-

 

7.0%

 

8.0%

 

-100 bps

Non current expenses

(75.8)

 

-

 

(75.8)

 

(41.7)

 

(34.1)

Operating income

272.5

 

(33.0)

 

239.5

 

302.8

 

(63.3)

% of revenue

6.0%

 

-

 

5.3%

 

7.1%

 

-180 bps

Financial result

(214.6)

 

70.4

 

(144.2)

 

(140.0)

 

(4.2)

Net income before tax

57.9

 

37.4

 

95.4

 

162.8

 

(67.4)

Income tax

(12.2)

 

(6.3)

 

(18.5)

 

(17.4)

 

(1.1)

Tax rate

21.0%

 

16.9%

 

19.4%

 

10.7%

 

+870 bps

Income from equity method

(0.8)

 

 

 

(0.8)

 

(0.2)

 

(0.5)

Minority Interests

(9.3)

 

-

 

(9.3)

 

(21.8)

 

12.5

Net result from continuing operations

35.7

 

31.1

 

66.9

 

123.4

 

(56.5)

Net result from discontinued operations

(13.7)

 

(1.1)

 

(14.8)

 

(9.6)

 

(5.3)

Net profit - Group share

22.1

 

30.0

 

52.0

 

113.8

 

(61.8)

% of revenue

0.5%

 

-

 

1.1%

 

2.7%

 

-160 bps

Note: 2021 figures restated to reflect IFRS5 discontinued operations and IAS 38 change in accounting regarding customization and configuration costs of SAAS solutions

BALANCE SHEET

Assets

   

in M€

 

31.12.2022

 

31.12.2021
restated*

Goodwill

 

3,237

 

3,214

Intangible assets

 

2,257

 

2,181

Property, plant and equipment

 

3,553

 

3,078

Rights of use

 

3,452

 

3,469

Financial assets

 

51

 

43

Equity-accounted investments

 

20

 

19

Deferred tax assets

 

87

 

98

Non-current assets

 

12,656

 

12,103

Inventories

 

29

 

28

Trade receivables and related accounts

 

440

 

365

Other receivables and currents assets

 

423

 

453

Current tax receivables

 

28

 

60

Financial instruments – assets

 

135

 

7

Cash and cash equivalents

 

734

 

1,215

Current assets

 

1,788

 

2,128

Assets held for sale

 

130

 

77

TOTAL ASSETS

 

14,574

 

14,308

     

Liabilities

   

in M€

 

31.12.2022

 

31.12.2021
restated*

Share capital

 

533

 

528

Premiums

 

1,206

 

1,196

Reserves and consolidated results

 

1,801

 

1,769

Equity attributable to owners of the Group

 

3,539

 

3,493

Non-controlling interests

 

329

 

271

Total shareholder’s equity

 

3,868

 

3,764

Provisions for pensions

 

88

 

99

Deferred tax liabilities

 

604

 

584

Other provisions

 

47

 

50

Loans and financial liabilities

 

3,560

 

3,761

Non-current lease liabilities

 

3,371

 

3,425

Other non-current liabilities

 

74

 

173

Non-current liabilities

 

7,743

 

8,093

Provisions for current liabilities

 

16

 

16

Trade payables and related accounts

 

571

 

500

Other payables and accruals

 

866

 

761

Current tax payables

 

32

 

69

Borrowings due within one year and bank overdrafts

 

948

 

681

Current lease liabilities

 

391

 

360

Financial instruments - Liabilities

 

0

 

21

Current liabilities

 

2,823

 

2,407

Liabilities associated with assets held for sale

 

139

 

44

TOTAL LIABILITIES

 

14,574

 

14,308

*Includes the impact of the IFRIC's final decision on the costs of
configuration and customizations of software used under a SaaS
contract

   

GROUP CASH FLOW STATEMENT

€m

 

YTD12 2022

 

IFRS 16 impact

 

YTD12 2022

 

YTD12 2021

 

Incl. IFRS 16

 

 

Excl. IFRS 16

 

Excl. IFRS 16

 

 

 

 

 

 

 

 

EBITDA

 

1,003

 

396

 

607

 

597

Non cash & others

 

3

 

29

 

(25)

 

(19)

Change in WC

 

36

 

2

 

33

 

(99)

Operating Capex

 

(98)

 

-

 

(98)

 

(80)

Operating cash flow

 

945

 

427

 

517

 

399

Income tax paid

 

(36)

 

-

 

(36)

 

(39)

Financial expenses paid/received

 

(180)

 

(70)

 

(110)

 

(121)

Free cash flow

 

728

 

357

 

371

 

239

Development Capex

 

(181)

 

-

 

(181)

 

(189)

Financial investments (bolt-on acquisitions)

 

(190)

 

-

 

(190)

 

(220)

Net Free cash flow

 

357

 

357

 

(1)

 

(171)

Dividends paid to Group shareholders

 

(26)

 

-

 

(26)

 

(15)

Real estate investments / divestments

 

(460)

 

-

 

(460)

 

(474)

Partnership Real Estate

 

45

 

-

 

45

 

344

Other net debt

 

(421)

 

(389)

 

(31)

 

(15)

Cash flow from discontinued operations

 

(19)

 

0

 

(19)

 

(9)

Net debt variation

 

(524)

 

(32)

 

(492)

 

(339)

 

 

 

 

 

 

 

 

Note: 2021 figures restated to reflect impacts from the final IFRIC decision relative to customization and configuration costs of SAAS solutions, and the impact of IFRS5 discontinued operations

INVESTOR RELATIONS

Sarah Mingham
VP Investor Relations
& Financing
sarah.mingham@korian.com
Tel: +33 (0)1 55 37 53 55

Charles Rungeard
Investor Relations
charles.rungeard@korian.com
Tel: +33 (0)6 86 75 29 51

MEDIA CONTACTS

Matthieu Desplats
Head of Press Relations
matthieu.desplats@korian.com
Tel: +33 (0)6 58 09 01 61

Julie Mary
Responsible for Press Relations
julie.mary@korian.com
Tel: +33 (0)6 59 72 50 69

Florian Bachelet
Responsible for Press Relations
florian.bachelet@korian.com
Tel: +33 (0)6 79 86 78 23

Source

KORIAN

Provider

BusinessWire

Company Name

KORIAN SE

ISIN

FR0010386334

Symbol

KORI

Market

Euronext